Seres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a research report released on Friday morning.

A number of other equities analysts also recently weighed in on MCRB. JPMorgan Chase & Co. downgraded Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 target price on shares of Seres Therapeutics in a report on Thursday, November 14th. Finally, Chardan Capital reiterated a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Trading Down 0.9 %

NASDAQ MCRB opened at $0.83 on Friday. The stock’s 50-day moving average price is $0.85 and its two-hundred day moving average price is $0.86. The company has a market cap of $142.18 million, a PE ratio of -3.62 and a beta of 2.11. Seres Therapeutics has a 1 year low of $0.54 and a 1 year high of $1.53.

Hedge Funds Weigh In On Seres Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Avantax Advisory Services Inc. increased its holdings in Seres Therapeutics by 170.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after buying an additional 28,500 shares during the last quarter. Jane Street Group LLC increased its holdings in Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock worth $49,000 after buying an additional 37,866 shares during the last quarter. Virtu Financial LLC increased its holdings in Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after buying an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC increased its holdings in Seres Therapeutics by 29.2% in the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after buying an additional 22,250 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock worth $218,000 after buying an additional 44,461 shares during the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.